Bicycle therapeutics announces publication of article highlighting preclinical data of tumor-targeted immune cell agonists (ticas™) in the journal for immunotherapy of cancer

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting preclinical studies of bicycle's novel, fully synthetic bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (ticas™) was published in the journal for immunotherapy of cancer (jitc). the article,
BCYC Ratings Summary
BCYC Quant Ranking